Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

70.48 

2.98 4.4%

as of Jun 22 '17 16:00

52 Week Range:

63.76 88.85


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Equity (BVPS) 1.79
1.86
2.28
3.54
3.66
4.06
6.13
7.09
9.05
12.25
12.88
growth rate 3.9% 22.6% 55.3% 3.4% 10.9% 51.0% 15.7% 27.6% 35.4% 5.1%
Earnings BIT -638.21
2,270.00
2,730.00
3,500.00
3,910.00
3,650.00
3,610.00
4,210.00
15,268.00
22,347.00
18,061.00
growth rate 100.0% 20.3% 28.2% 11.7% -6.7% -1.1% 16.6% 262.7% 46.4% -19.2%
Avg.PE -23.90
27.47
24.39
15.34
10.91
11.53
22.42
41.32
14.09
7.40
7.12
growth rate 100.0% -11.2% -37.1% -28.9% 5.7% 94.5% 84.3% -65.9% -47.5% -3.8%
ROA -30.31
32.56
31.29
31.53
27.25
19.41
13.45
14.06
42.34
41.87
24.81
growth rate 100.0% -3.9% 0.8% -13.6% -28.8% -30.7% 4.5% 201.1% -1.1% -40.8%
ROE -49.14
61.24
52.84
50.11
47.44
44.49
32.30
29.74
90.32
106.64
72.16
growth rate 100.0% -13.7% -5.2% -5.3% -6.2% -27.4% -7.9% 203.7% 18.1% -32.3%
ROIC -39.79
38.67
38.43
40.46
34.41
24.45
17.87
18.56
54.26
54.52
33.19
growth rate 100.0% -0.6% 5.3% -15.0% -29.0% -26.9% 3.9% 192.4% 0.5% -39.1%
Cur. Ratio 3.18
4.11
3.52
2.57
2.32
5.53
1.44
1.15
3.07
2.50
2.22
growth rate 29.3% -14.4% -27.0% -9.7% 138.4% -74.0% -20.1% 167.0% -18.6% -11.2%
Quick Ratio 2.02
2.67
2.30
1.63
1.51
4.71
0.85
0.67
2.56
2.07
1.78
growth rate 32.2% -13.9% -29.1% -7.4% 211.9% -82.0% -21.2% 282.1% -19.1% -14.0%
Leverage 2.25
1.69
1.69
1.52
1.98
2.57
2.28
1.98
2.25
2.80
3.02
growth rate -24.9% 0.0% -10.1% 30.3% 29.8% -11.3% -13.2% 13.6% 24.4% 7.9%
Balance Sheet Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Acct.Receivable 1,023.40
1,389.50
1,622.00
2,159.32
2,014.03
2,513.00
5,143.00
6,682.00
5,371.00
growth rate 35.8% 16.7% 33.1% -6.7% 24.8% 104.7% 29.9% -19.6%
Acct.Payable 2,438.55
2,965.25
3,599.00
5,144.00
8,468.00
9,017.00
growth rate 21.6% 21.4% 42.9% 64.6% 6.5%
Cur.Assets 4,278.40
4,812.60
5,708.10
13,918.79
6,156.35
6,997.00
17,714.00
24,762.00
20,445.00
growth rate 12.5% 18.6% 143.8% -55.8% 13.7% 153.2% 39.8% -17.4%
Total Assets 6,936.80
9,698.60
11,592.60
17,303.13
21,239.84
22,579.00
34,664.00
51,716.00
56,977.00
growth rate 39.8% 19.5% 49.3% 22.8% 6.3% 53.5% 49.2% 10.2%
Cash 1,459.30
1,273.00
907.90
9,883.78
1,803.69
2,113.00
10,027.00
12,851.00
8,229.00
growth rate -12.8% -28.7% 988.6% -81.8% 17.2% 374.5% 28.2% -36.0%
Inventory 927.90
1,051.80
1,203.80
1,389.98
1,744.98
1,697.00
1,386.00
1,955.00
1,587.00
growth rate 13.4% 14.5% 15.5% 25.5% -2.8% -18.3% 41.1% -18.8%
Cur.Liabilities 1,221.00
1,871.60
2,465.00
2,514.79
4,237.90
6,407.00
5,761.00
9,890.00
9,219.00
growth rate 53.3% 31.7% 2.0% 68.5% 51.2% -10.1% 71.7% -6.8%
Liabilities 2,664.30
3,331.50
5,728.90
10,564.28
11,930.10
11,145.00
19,223.00
33,180.00
38,090.00
growth rate 25.0% 72.0% 84.4% 12.9% -6.6% 72.5% 72.6% 14.8%
LT Debt 1,300.00
1,300.00
1,154.60
1,242.80
2,838.60
7,605.73
7,054.56
3,939.00
11,921.00
21,073.00
26,346.00
growth rate 0.0% -11.2% 7.6% 128.4% 167.9% -7.3% -44.2% 202.6% 76.8% 25.0%
Equity 1,815.72
3,459.99
4,272.60
6,367.10
5,863.70
6,738.86
9,302.59
11,370.00
15,426.00
18,534.00
18,887.00
growth rate 90.6% 23.5% 49.0% -7.9% 14.9% 38.0% 22.2% 35.7% 20.2% 1.9%
Common Shares 1,836.00
1,929.00
1,918.00
1,868.00
1,747.00
1,580.00
1,583.00
1,695.00
1,647.00
1,521.00
1,358.00
growth rate 5.1% -0.6% -2.6% -6.5% -9.6% 0.2% 7.1% -2.8% -7.7% -10.7%
Cash Flow Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Capital Expenditures 105.21
78.65
115.01
230.06
61.88
131.90
397.00
190.00
557.00
747.00
748.00
growth rate -25.2% 46.2% 100.0% -73.1% 113.2% 201.0% -52.1% 193.2% 34.1% 0.1%
Cash Dividends 0.00
0.00
0.00
0.00
-131.50
115.00
0.00
0.00
1,874.00
1,874.00
2,455.00
growth rate 100.0% -100.0% 0.0% 31.0%
Cash From OA 1,218.06
1,669.08
2,143.40
3,080.10
2,833.90
3,639.01
3,195.00
3,105.00
12,818.00
20,329.00
16,669.00
growth rate 37.0% 28.4% 43.7% -8.0% 28.4% -12.2% -2.8% 312.8% 58.6% -18.0%
FCF per Share 0.52
0.87
1.09
1.53
1.59
2.02
1.77
1.61
6.01
11.40
12.42
growth rate 67.3% 25.3% 40.4% 3.9% 27.0% -12.4% -9.0% 273.3% 89.7% 9.0%
Sale Purchase of Stock -2,286.43
-70.00
-117.00
-4,983.00
-9,495.00
-10,883.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
FCF 1,113.00
1,687.00
2,090.00
2,850.00
2,772.00
3,507.00
2,798.00
2,914.00
12,261.00
19,582.00
15,921.00
growth rate 51.6% 23.9% 36.4% -2.7% 26.5% -20.2% 4.2% 320.8% 59.7% -18.7%
Income Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Sales 3,030.00
4,230.00
5,335.80
7,011.40
7,949.40
8,385.39
9,702.00
11,202.00
24,890.00
32,639.00
30,390.00
growth rate 39.6% 26.1% 31.4% 13.4% 5.5% 15.7% 15.5% 122.2% 31.1% -6.9%
Op.Income 2,678.50
3,529.20
3,962.20
2,803.64
2,592.00
3,075.00
15,265.00
22,193.00
17,633.00
growth rate 31.8% 12.3% -29.2% -7.6% 18.6% 396.4% 45.4% -20.6%
IBT 2,672.70
3,502.00
3,913.50
3,651.00
3,612.00
4,208.00
14,856.00
21,659.00
17,097.00
growth rate 31.0% 11.8% -6.7% -1.1% 16.5% 253.0% 45.8% -21.1%
Net Income 1,978.90
2,635.80
2,901.30
2,803.64
2,592.00
3,075.00
12,101.00
18,108.00
13,501.00
growth rate 33.2% 10.1% -3.4% -7.6% 18.6% 293.5% 49.6% -25.4%
EPS -0.65
0.84
1.03
1.41
1.66
1.77
1.64
1.81
7.35
11.91
9.94
growth rate 100.0% 22.6% 36.9% 17.7% 6.6% -7.3% 10.4% 306.1% 62.0% -16.5%
Gross Profit 2,592.82
3,461.27
4,208.50
5,415.80
6,079.50
6,260.98
7,231.00
8,343.00
21,102.00
28,633.00
26,129.00
growth rate 33.5% 21.6% 28.7% 12.3% 3.0% 15.5% 15.4% 152.9% 35.7% -8.8%
R&D 721.80
939.90
1,072.90
1,229.15
1,760.00
2,120.00
2,854.00
3,014.00
5,098.00
growth rate 30.2% 14.2% 14.6% 43.2% 20.5% 34.6% 5.6% 69.1%

Quarterly Statements

Item Name Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Earnings BIT 4,732.00
4,626.00
4,518.00
4,185.00
3,878.00
growth rate -2.2% -2.3% -7.4% -7.3%
Balance Sheet Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Acct.Receivable 6,993.00
6,587.00
5,837.00
5,371.00
4,034.00
growth rate -5.8% -11.4% -8.0% -24.9%
Acct.Payable 8,636.00
9,399.00
10,012.00
9,017.00
8,282.00
growth rate 8.8% 6.5% -9.9% -8.2%
Cur.Assets 19,267.00
18,353.00
21,425.00
20,445.00
21,424.00
growth rate -4.7% 16.7% -4.6% 4.8%
Total Assets 47,765.00
49,980.00
56,609.00
56,977.00
57,701.00
growth rate 4.6% 13.3% 0.7% 1.3%
Cash 6,315.00
6,485.00
9,809.00
8,229.00
10,285.00
growth rate 2.7% 51.3% -16.1% 25.0%
Inventory 1,880.00
1,862.00
1,900.00
1,587.00
1,474.00
growth rate -1.0% 2.0% -16.5% -7.1%
Cur.Liabilities 10,910.00
10,444.00
11,073.00
9,219.00
8,282.00
growth rate -4.3% 6.0% -16.7% -10.2%
Liabilities 34,367.00
34,444.00
39,741.00
38,090.00
37,260.00
growth rate 0.2% 15.4% -4.2% -2.2%
LT Debt 21,077.00
21,427.00
26,371.00
26,346.00
26,321.00
growth rate 1.7% 23.1% -0.1% -0.1%
Equity 13,398.00
15,536.00
16,868.00
18,887.00
20,441.00
growth rate 16.0% 8.6% 12.0% 8.2%
Common Shares 1.00
1.00
1.00
1.00
growth rate 0.0% 0.0% 0.0%
Cash Flow Statement Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Capital Expenditures 177.00
204.00
198.00
169.00
118.00
growth rate 15.3% -2.9% -14.7% -30.2%
Cash Dividends 587.00
626.00
623.00
619.00
687.00
growth rate 6.6% -0.5% -0.6% 11.0%
Cash From OA 3,913.00
4,723.00
4,330.00
3,486.00
2,925.00
growth rate 20.7% -8.3% -19.5% -16.1%
Sale Purchase of Stock -7,867.00
-974.00
-1,022.00
-979.00
-469.00
growth rate 0.0% 0.0% 0.0% 0.0%
FCF 3,736.00
4,519.00
4,132.00
3,317.00
2,807.00
growth rate 21.0% -8.6% -19.7% -15.4%
Income Statement Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Sales 7,794.00
7,776.00
7,500.00
7,320.00
6,505.00
growth rate -0.2% -3.6% -2.4% -11.1%
Op.Income 3,566.00
4,538.00
4,399.00
4,045.00
3,767.00
growth rate 27.3% -3.1% -8.1% -6.9%
IBT 4,502.00
4,399.00
4,276.00
3,920.00
3,617.00
growth rate -2.3% -2.8% -8.3% -7.7%
Net Income 3,566.00
3,497.00
3,330.00
3,108.00
2,702.00
growth rate -1.9% -4.8% -6.7% -13.1%
EPS
growth rate
Gross Profit 6,601.00
6,912.00
6,371.00
6,245.00
5,548.00
growth rate 4.7% -7.8% -2.0% -11.2%
R&D 1,265.00
1,484.00
1,141.00
1,208.00
931.00
growth rate 17.3% -23.1% 5.9% -22.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.33)

YOY Growth Grade:

C (60.70)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 6.85 7.45 8.72
EPS / Growth 61.3% 9.46 -5.6%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 17.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 9.5% 9.5%
Future PE 2.00 11.50 11.50
Future EPS 10.45 23.36 23.36
Value Price
MOS %
5.17
-92.7%
66.40
-5.8%
66.40
-5.8%
MOS Price 2.58 33.20 33.20
IRT 7.15 5.49 5.49

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.